Roche dumps its cancer drug R&D pact with Wilex

Roche ($RHHBY) is bowing out of a two-year-old collaboration with a subsidiary of a struggling Wilex. The Munich-based biotech says that Roche is backing away from their development deal on antibody-targeted amanitin conjugates as the pharma giant has been deprioritizing research deals that fall outside of immuno-oncology. Wilex's lead drug, Rencarex, failed a Phase III trial in 2012. Release

Suggested Articles

The deal gives J&J a stake in the development and commercialization of anticoagulants including phase 2-ready secondary stroke candidate BMS-986177.

Boehringer gained the global rights to OSE's SIRP-alpha antagonist, which is in development for solid tumors.

Lilly is diving into encapsulated beta cell treatments, designed to restore insulin production in patients with Type 1 diabetes.